The medical device clinical trial terminations and suspensions in Q2 2022 saw a 34% decrease in the number of trials globally when compared with the last four – quarters average, according to GlobalData’s medical devices database.
The global medical devices market was worth $540.69bn in 2021 and is expected to reach $523.13bn by 2023, according to GlobalData’s analysis.
Go deeper with GlobalData
Medical devices clinical trials by market: Cardiovascular Devices has the most terminations and suspensions
Looking at the clinical trial terminations and suspensions by the type of markets, Cardiovascular Devices accounted for the largest proportion (20%) in Q2 2022, followed by Neurology Devices (15%) and Orthopedic Devices (9%).
See Also:
Of the global medical devices market value, the Cardiovascular Devices market held a 10% share worth $55bn in 2021 and is expected to reach $59.97bn by 2023.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Middle East and Africa tops terminated and suspended trials activity
Comparing medical device clinical trial terminations and suspensions in different regions of the globe, Middle East and Africa held the top position with a 34% share during Q2 2022, followed by Asia-Pacific with 25%, and North America with 22%.
On a country level, Israel had the largest share (34%) of the global clinical trial terminations and suspensions during the quarter. In second place was The US with a share of 20%, followed by China with 8%.
Looking at the share of activity of sponsored clinical trials in terms of terminations and suspensions, company-sponsored trials accounted for a 34% share, while institute-sponsored trials held the remaining share.
The quarterly average for the last four quarters saw company-sponsored trials account for 44% of terminations and suspensions, while institute-sponsored trials account for 56%.
Methodology
The clinical trials data used for the analysis were extracted from the medical Clinical Trials Database of GlobalData’s Medical Intelligence Center. Medical device clinical trials database covers all clinical trials conducted on medical devices, combination devices, diagnostics, and diagnostic imaging agents covering 16 markets (as per medical device taxonomy). GlobalData tracks clinical trials from six key registries: NCT, UMIN, ACTRN, ChiCTR, EudraCT, and ISRCT. It also monitors universities, company websites, press releases, investor presentations and annual reports to track medical device clinical trials. Industry refers to commercial entities such as private and public companies and their subsidiaries. Non-Industry refers to non-profit making entities including hospitals, universities, government research institutions and non-government research institutions. The information is collected by following systematic research techniques and proprietary methodology. Only terminated, suspended and withdrawn clinical trials are considered for this analysis.
